**Additional file 3: The subgroup of patients with follow-up TEE-examination four weeks after PMVR does not differ from the remaining study sample concerning sex, age or clinical manifestation of MR. VCAr is higher in the follow-up sample.**

|  |  |  |  |
| --- | --- | --- | --- |
|  | Follow-up(n=7) | Remaining sample(n=22) | p-value |
| Sex - female | 3 | 9 | 0.93 |
| Age [years] | 80.4 ± 6.1 | 76.0 ± 5.4 | 0.08 |
| BMI [kg/m2] | 27.0 ± 5.5 | 25.1±3.6 | 0.31 |
| Degenerative MR | 1 | 9 | 0.20 |
| NYHA  | 3 (3; 4) | 3 (2; 3) | 0.39 |
| logEuroScore | 22.1 (10.3; 34.7) | 18.5 (12.7; 31.5) | 0.98 |
| MR grade before PMVR | 4 (3; 4) | 4 (3.5; 4) | 0.26 |
| Vena contracta width [mm] | 8 (5; 9) | 7 (6; 8) | 0.75 |
| NT-proBNP [pg/ml] | 5336 (2529; 6782) | 3083 (1472; 4888) | 0.37 |

*Data are shown as absolute numbers, mean ± standard deviation, median (P25; P75), respectively. TEE: transoesophageal echocardiography. PMVR: percutaneous mitral valve repair. MR: mitral regurgitation. VC: vena contracta. VCAr: VCAratio=VCA after PMVR / VCA before PMVR. BMI: body-mass index. NYHA: New York Heart Association functional classification.*